SEC Form 4 · accession 0001209191-15-048302
Viking Therapeutics, Inc. · VKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
LIGAND PHARMACEUTICALS INC
10% Owner
Period of report
May 28, 2015
Accepted (ET)
Jun 1, 2015 · 4:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001607678
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | May 28, 2015 | J | 228,105 | $0.00 | A | 4,780,964 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares of Common Stock were acquired as partial consideration for licenses granted to the Issuer by Ligand Pharmaceuticals Incorporated ("Ligand") pursuant to the Master License Agreement, dated May 21, 2014, among Ligand, Metabasis Therapeutics, Inc. ("Metabasis"), a wholly-owned subsidiary of Ligand, and the Issuer, as amended by the First Amendment to Master License Agreement, dated September 6, 2014 and the Second Amendment to Master License Agreement, dated April 8, 2015.
- F2Includes 55,060 shares acquired by Metabasis.
- F3Includes 882,474 shares held by Metabasis.